Hypopharyngeal Cancer

Our multidisciplinary team has extensive experience in diagnosing and treating hypopharyngeal cancer, which develops in the hypopharynx, the bottom part of the throat. Our surgeons, medical oncologists, and radiation oncologists collaborate to create a treatment plan based on the location of the tumor, its size, and how far it has spread. The goal is to find the right combination of treatments to destroy hypopharyngeal cancer while preserving organ function.

Clinical Trials and Research Studies

Phase 1

An Open Label Phase 1 Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 with Pembrolizumab Following Radiation Therapy in the Treatment of Non-Small-Cell Lung Cancer Triple-Negative Breast Cancer or Squamous Cell Carcinoma of the Head and Neck that has Progressed on Checkpoint Inhibitors

Learn More

Phase 4

A phase 4 single-arm open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.

Learn More

Phase 1

A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)

Learn More

Phase 5

First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Learn More